Dr Samantha Loveless
(hi/ei)
BSc (Cardiff), PhD (Cardiff)
Timau a rolau for Samantha Loveless
Rheolwr Labordy, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
Trosolwyg
Ar hyn o bryd rwy'n cael fy nghyflogi fel y Rheolwr Bioystorfa a Labordy ar gyfer y Lab Niwroleg Academaidd sydd wedi'i leoli ar gampws Prifysgol Caerdydd.
Mae fy rôl yn cynnwys rheoli Banc Meinwe Niwrowyddoniaeth Cymru (WNRTB); cymeradwyo, cydsynio, casglu, storio a dyrannu samplau cleifion niwroleg ar gyfer y biobanc, yn ogystal â phrosiectau niwroleg penodol eraill (ERYRI, Epilepsi-Bio) a breichiau biofancio treialon clinigol Sglerosis Ymledol (MS) (megis Octopus a DELIVER-MS), cydlynu casglu a dosbarthu samplau ar draws sawl safle cenedlaethol a rhyngwladol.
Rwy'n rheoli'r labordy a'r cyfleusterau yn ogystal â thîm o dechnegwyr ymchwil ar gyfer y grŵp ymchwil MS ac Uned BRAIN, gan gefnogi ymchwil i ystod eang o anhwylderau gan gynnwys MS, NMO, epilepsi, MND, glioblastoma, IIH.
Mae fy ymchwil yn canolbwyntio'n bennaf ar fiofarcwyr hylif mewn MS gyda sawl papur cydweithredol wedi'u cyhoeddi hyd yma.
Cyhoeddiad
2026
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- Underwood, J. et al., 2026. Bloodstream infections and Blood-Brain barrier Permeability: An observational cohort study. Brain, Behavior, and Immunity 135 106518. (10.1016/j.bbi.2026.106518)
- Kreft, K. L. et al. 2026. Genetic subtypes associated with multiple sclerosis severity and response to treatment. Journal of Neurology, Neurosurgery and Psychiatry 97 (5), pp.413-421. (10.1136/jnnp-2025-337337)
2025
- Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8), pp.1007-1010. (10.1177/13524585251330962)
2024
- Gelissen, L. M. et al., 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90 105796. (10.1016/j.msard.2024.105796)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
2023
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
2022
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
2021
- Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)
- Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
2020
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Naughton, M. et al., 2020. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17 (1) 349. (10.1186/s12974-020-02025-7)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
- Yeo, T. et al., 2020. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports 10 12381. (10.1038/s41598-020-69119-3)
2019
- Castle, D. et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19 (4), pp.342-349. (10.1136/practneurol-2018-002000)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
2018
- Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28 (12), pp.1682-1693. (10.1089/thy.2018.0232)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28 (4), pp.507-520. (10.1111/bpa.12546)
2017
- Welton, J. L. et al., 2017. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. Journal of Extracellular Vesicles 6 (1) 1369805. (10.1080/20013078.2017.1369805)
- Hakobyan, S. et al. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23 (7), pp.946-955. 135245851666900. (10.1177/1352458516669002)
2016
- Watkins, L. M. et al., 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13 161. (10.1186/s12974-016-0611-x)
2015
- Willis, M. et al. 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22 (4), pp.732-735. (10.1111/ene.12564)
2014
- Ingram, G. et al. 2014. Complement activation in MS: An immunohistochemical analysis. Journal of Neurology, Neurosurgery & Psychiatry 85 (10), pp.e4.13. (10.1136/jnnp-2014-309236.11)
- Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2 53. (10.1186/2051-5960-2-53)
- Stewart, J. P. et al., 2014. Seroprevalence of molluscum contagiosum virus in German and UK populations. PLoS ONE 9 (2) e88734. (10.1371/journal.pone.0088734)
2012
- Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18 (10), pp.1401-1411. (10.1177/1352458512438238)
2011
- Ingram, G. et al. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112 (10), pp.2653-2654. (10.1002/jcb.23204)
2010
- Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133 (6), pp.1602-1611. (10.1093/brain/awq085)
- Ingram, G. et al. 2010. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology 17 (11), pp.1386-1389. (10.1111/j.1468-1331.2010.03083.x)
Erthyglau
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- Underwood, J. et al., 2026. Bloodstream infections and Blood-Brain barrier Permeability: An observational cohort study. Brain, Behavior, and Immunity 135 106518. (10.1016/j.bbi.2026.106518)
- Kreft, K. L. et al. 2026. Genetic subtypes associated with multiple sclerosis severity and response to treatment. Journal of Neurology, Neurosurgery and Psychiatry 97 (5), pp.413-421. (10.1136/jnnp-2025-337337)
- Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8), pp.1007-1010. (10.1177/13524585251330962)
- Gelissen, L. M. et al., 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90 105796. (10.1016/j.msard.2024.105796)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
- Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)
- Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Naughton, M. et al., 2020. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17 (1) 349. (10.1186/s12974-020-02025-7)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
- Yeo, T. et al., 2020. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports 10 12381. (10.1038/s41598-020-69119-3)
- Castle, D. et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19 (4), pp.342-349. (10.1136/practneurol-2018-002000)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28 (12), pp.1682-1693. (10.1089/thy.2018.0232)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28 (4), pp.507-520. (10.1111/bpa.12546)
- Welton, J. L. et al., 2017. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. Journal of Extracellular Vesicles 6 (1) 1369805. (10.1080/20013078.2017.1369805)
- Hakobyan, S. et al. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23 (7), pp.946-955. 135245851666900. (10.1177/1352458516669002)
- Watkins, L. M. et al., 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13 161. (10.1186/s12974-016-0611-x)
- Willis, M. et al. 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22 (4), pp.732-735. (10.1111/ene.12564)
- Ingram, G. et al. 2014. Complement activation in MS: An immunohistochemical analysis. Journal of Neurology, Neurosurgery & Psychiatry 85 (10), pp.e4.13. (10.1136/jnnp-2014-309236.11)
- Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2 53. (10.1186/2051-5960-2-53)
- Stewart, J. P. et al., 2014. Seroprevalence of molluscum contagiosum virus in German and UK populations. PLoS ONE 9 (2) e88734. (10.1371/journal.pone.0088734)
- Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18 (10), pp.1401-1411. (10.1177/1352458512438238)
- Ingram, G. et al. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112 (10), pp.2653-2654. (10.1002/jcb.23204)
- Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133 (6), pp.1602-1611. (10.1093/brain/awq085)
- Ingram, G. et al. 2010. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology 17 (11), pp.1386-1389. (10.1111/j.1468-1331.2010.03083.x)
Contact Details
[email protected]
+44 29207 43454
Prif Adeilad yr Ysbyty, Llawr 4ydd Llawr, Coridor B-C, Ystafell 80G, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29207 43454
Prif Adeilad yr Ysbyty, Llawr 4ydd Llawr, Coridor B-C, Ystafell 80G, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN